Abstract

Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis

Author(s): Song Guiyun, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S

Issue: Jul/Aug 2020 - Volume 24, Number 4

Page(s): 337-345

Download in electronic PDF format for $75
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 1
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 2
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 3
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 4
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 5
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 6
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 7
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 8
  • Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Page 9

Abstract

Psoriasis is an inflammation-mediated skin disorder for which an efficacious topical treatment is yet to be identified. A new compounded topical formulation containing 10% pentoxifylline in XemaTop base was recently developed for psoriasis. Prior to its use in humans, an in vitro evaluation was performed to determine its efficacy in attenuating molecular markers associated with psoriasis using a three-dimensional psoriasis tissue model. After 5 days of topical exposure to the formulation, the levels of inflammatory cytokines IL-1ß, IL-6, and GM-CSF decreased by 20%, 94%, and 96%, respectively. The production of pro-collagen type I and fibronectin essential for cellular proliferation was also significantly inhibited with a concomitant thinning of the epidermis. These results suggest that 10% pentoxifylline in XemaTop is efficacious in inhibiting the biomarkers associated with psoriasis. Pentoxifylline in XemaTop was stable within 91 days when stored under refrigerated or ambient conditions. These biochemical and stability studies suggest that 10% pentoxifylline in XemaTop may be evaluated now in psoriasis patients.

Related Keywords

  • pentoxifylline
  • XemaTop base
  • psoriasis
  • inflammatory skin diseases
  • skin cell hyperproliferation
  • inflammation
  • topical preparation
  • inflammatory cytokines
  • keratinocytes
  • pro-collagen type I
  • fibronectin
  • epidermal thinning
  • stability
  • preclinical study

Related Categories

  • DERMATOLOGY
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • ALLERGY/IMMUNOLOGY/INFLAMMATION
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2020
Pg. 337-345
Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis
Author(s): Song Guiyun, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S
May/Jun 2017
Pg. 205-211
Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report
Author(s): Jones Nat, Carvalho Maria, Branvold-Herr Andrea
Sep/Oct 2015
Pg. 357-365
Novel Approaches to Topical Psoriasis Therapy
Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
Nov/Dec 2014
Pg. 512-515
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Author(s): Heustess Allie, Asbill Scott, Eagerton David, Arnold John
Jan/Feb 2012
Pg. 80-81
Chemical Stability of Pentoxifylline in a Topical Cream
Author(s): Gupta Vishnu D
Nov/Dec 2003
Pg. 460-463
View Sample
Basics of Compounding for Dry-Skin Conditions
Author(s): Allen Loyd V Jr
Nov/Dec 1999
Pg. 496-500
Enhancement of Skin Penetration of Nonsteroidal Anti-Inflammatory Drugs from Extemporaneously Compounded Topical-Gel Formulations
Author(s): Goodwin Donald A, Fuhram L Clifton
Sep/Oct 2009
Pg. 386-389
Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Author(s): Williams LaVonn A, Fokken Dawn
May/Jun 2011
Pg. 204-213
Treatment Options for Psoriasis
Author(s): Williams LaVonn A, Humphreys Erica
Jan/Feb 2023
Pg. 57
Psoriasis Topical Ointment
Author(s): Allen Loyd V Jr
Jul/Aug 2022
Pg. 329
Psoriasis Topical Ointment
Author(s): Allen Loyd V Jr
Mar/Apr 2018
Pg. 154-163
Evaluation and Comparison of Wound Healing Properties of an Ointment (AlpaWash) Containing Brazilian Micronized Propolis and Peucedanum ostruthium Leaf Extract in Skin Ulcer in Rats
Author(s): Nani Marcel, Leone Andréia, Bom Vinícius Pedro, Buszinski Andrei Felipe, Oliveira de Souza Rebeca, Pinheiro Vanessa Alves, Danapoulos Panagiota, Swikidisa Rosita, Marquele-Oliveira Franciane, Cipriani Frade Marco Andrey, Berretta Andresa Aparecida, Nogueira Rodrigo José Lupatini
Jan/Feb 2016
Pg. 6-10
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis
Author(s): Choo Winnie
Jul/Aug 2022
Pg. 270-274
A Compendium of Compounding Agents and Formulations, Part 4: Nifedipine and Pentoxifylline
Author(s): Riepl Mike
Nov/Dec 2019
Pg. 496-503
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Author(s): Shakshuki Ayah, Agu Remigius U
Jul/Aug 2004
Pg. 313-319
Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Author(s): Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Jul/Aug 2020
Pg. 320
Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream)
Author(s): Allen Loyd V Jr
May/Jun 2014
Pg. 256-261
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Author(s): Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
Mar/Apr 2004
Pg. 101-105
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K